Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Innate Pharma SA ( (FR:IPH) ).
On November 17, 2025, Innate Pharma announced its participation in the Jefferies Global Healthcare Conference in London. The company’s executive team engaged in one-on-one meetings and presented their latest developments, showcasing Innate Pharma’s strategic focus on advancing innovative cancer immunotherapies. This participation underscores Innate Pharma’s commitment to maintaining a strong presence in the global healthcare industry and highlights its ongoing efforts to collaborate with key stakeholders to enhance its market positioning.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company specializes in antibody-engineering and innovative target identification, advancing a portfolio of potential first and/or best-in-class assets. Innate Pharma collaborates with leading biopharmaceutical companies and academic institutions to drive innovation in immuno-oncology. It is headquartered in Marseille, France, with a US office in Rockville, MD, and is listed on Euronext Paris and Nasdaq.
YTD Price Performance: -17.87%
Average Trading Volume: 281,850
Technical Sentiment Signal: Strong Sell
Current Market Cap: €146.2M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.